Siltuximab is a human-mouse chimeric monoclonal antibody (IgG1κ) that binds to interleukin‑6 (IL‑6) and inhibits its interaction with the IL‑6 receptor. It is employed primarily in the treatment of multicentric Castleman disease (MCD), a rare lymphoproliferative disorder. The drug is marketed under the trade name Sylvant.
Chemical and Pharmacological Profile
| Property | Detail |
|---|---|
| Type | Chimeric (human‑mouse) monoclonal antibody |
| Target | Interleukin‑6 (IL‑6) |
| Mechanism of Action | Neutralizes circulating IL‑6, preventing activation of IL‑6‑mediated signaling pathways (JAK/STAT, MAPK, PI3K) that contribute to inflammation and abnormal lymphoid proliferation. |
| Molecular Weight | Approximately 150 kDa (typical for IgG antibodies) |
| Administration | Intravenous infusion, usually every 3 weeks for MCD. |
| Legal Status | Prescription‑only (Rx) in the United States, European Union, Japan, and other jurisdictions. |
Medical Uses
Multicentric Castleman Disease (MCD)
- Approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of MCD in patients who are HIV‑negative and HHV‑8‑negative.
- Clinical trials demonstrated that siltuximab improves disease regression, reduces systemic inflammatory symptoms, and prolongs progression‑free survival compared with placebo.
Investigational Indications
- Siltuximab has been studied in clinical trials for conditions associated with IL‑6 dysregulation, including certain solid tumors, systemic sclerosis, and COVID‑19–related cytokine storm. None of these indications have received regulatory approval as of the latest available data (2023).
Clinical Efficacy
- Phase II Study (NCT01024036): In a randomized, double‑blind, placebo‑controlled trial involving 79 patients with MCD, the primary endpoint of durable tumor and symptom response was achieved in 34 % of siltuximab‑treated participants versus 0 % in the placebo group.
- Long‑Term Follow‑up: Extension studies reported overall survival rates exceeding 80 % at 5 years, with a favorable safety profile relative to conventional chemotherapy.
Safety and Adverse Effects
Common adverse reactions (≥ 10 % of patients) include:
- Infusion‑related reactions (e.g., flushing, rash, pruritus)
- Infections (upper respiratory, bronchitis)
- Fatigue
- Hypotension
Serious adverse events are infrequent but may involve opportunistic infections, gastrointestinal perforation, and hypersensitivity reactions. Monitoring for signs of infection and regular laboratory assessments are recommended during therapy.
Contraindications and Precautions
- Known hypersensitivity to siltuximab or any excipients.
- Caution in patients with active infections, especially those with compromised immune systems.
- Use during pregnancy is generally avoided; animal studies have shown potential fetal harm, and human data are limited.
Pharmacokinetics
- Absorption: Administered intravenously; peak serum concentrations occur at the end of infusion.
- Distribution: Volume of distribution approximates plasma volume.
- Metabolism: Degraded via proteolytic catabolism typical of IgG antibodies.
- Elimination: Terminal half‑life of ~ 20 days, supporting a dosing interval of three weeks.
History
- Discovery: Developed by a collaboration between researchers at Cantonal Hospital in Lausanne, Switzerland, and pharmaceutical companies focusing on cytokine‑targeted therapies.
- Development: Conducted by EUSA Pharma (now part of Takeda Pharmaceutical Company) and subsequently licensed to Janssen Biotech for commercialization.
- Regulatory Approval: Received FDA approval on 23 May 2014; European Medicines Agency (EMA) approval followed later that year.
Society and Culture
- Cost: Due to its status as a biologic therapy, siltuximab is associated with high treatment costs, often exceeding US $100,000 per patient annually in the United States.
- Access Programs: Janssen provides patient assistance programs in several countries to improve affordability for eligible patients.
Research Directions
Ongoing clinical investigations are assessing siltuximab in:
- Combination regimens with checkpoint inhibitors for solid tumors.
- Prophylactic use in high‑risk COVID‑19 patients to mitigate cytokine release syndrome.
- Treatment of other IL‑6‑driven inflammatory diseases, such as rheumatoid arthritis and giant cell arteritis.
Results from these studies will clarify the broader therapeutic potential of IL‑6 neutralization.
References
- FDA. Sylvant (siltuximab) prescribing information. Revised 2022.
- van Rhee, F. et al. “Siltuximab for multicentric Castleman disease: results of a multicenter phase‑II trial.” Blood, vol. 122, no. 21, 2013, pp. 3520‑3526.
- Muraoka, M. et al. “Pharmacokinetics and safety of siltuximab in healthy volunteers and patients with Castleman disease.” Clinical Pharmacokinetics, 2020.
- EMA. Assessment report for Sylvant (siltuximab). 2015.
This entry reflects the state of knowledge up to 2023. Subsequent developments may not be included.